Sequoia
staked its fate to the performance of Valeant Pharmaceuticals, a firm adored
by hedge fund
managers and Sequoia — which plowed over a third of its
portfolio into the stock — for its singular strategy: buy small drug companies with successful niche medicines, then skyrocket the price of those drugs.